Electrocardiographic identification of left ventricular hypertrophy: test performance in relation to definition of hypertrophy and presence of obesity

Department of Medicine, New York Hospital-Cornell Medical Center, New York 10021, USA.

OBJECTIVES. This study sought to assess a test performance of the electrocardiogram (ECG) in relation to 1) varying definitions of left ventricular hypertrophy based on different methods of adjusting left ventricular mass for body size, and 2) the presence or absence of obesity. BACKGROUND. Although left ventricular mass is most commonly indexed for body surface area or height when defining left ventricular hypertrophy, recent work suggests that normalization for height to the power of 2.7 (height2.7) may decrease variability among normal subjects and correctly identify the impact of obesity on hypertrophy. METHODS. The product of Cornell voltage and QRS duration (Cornell product) and Framingham-adjusted Cornell voltage were determined from 12-lead ECGs in 212 patients. Left ventricular hypertrophy was defined on the basis of left ventricular mass indexed to body surface area, height and height2.7. RESULTS. Using partitions with matched specificity of 95%, the sensitivity of ECG criteria varied with the definition of hypertrophy, ranging from 39% to 52% for the Cornell product and from 24% to 33% for adjusted Cornell voltage. When left ventricular mass was indexed to body surface area or to height2.7, the 52% and 39% sensitivities of the Cornell product were significantly greater than the 24% (p < 0.001) and 29% (p < 0.05) sensitivities of adjusted Cornell voltage, with a similar trend when left ventricular mass was indexed to height (43% vs. 33%, p = 0.10). Comparison of receiver operating characteristic curves confirmed the superior overall performance of the Cornell product relative to adjusted Cornell voltage for hypertrophy defined by body surface area and height2.7 and demonstrated greater reproducibility of overall performance, as measured by the coefficient of variability, for the Cornell product (1.7%) than for adjusted Cornell voltage (5.8%). Sensitivity of adjusted Cornell voltage was significantly greater in obese than in nonobese subjects (50% to 59% vs. 18% to 24%, p < 0.01), but the Cornell product had only minimally higher sensitivity in nonobese than in obese subjects (40% to 54% vs. 32% to 44%, p = NS). CONCLUSIONS. The ability of ECG criteria to detect left ventricular hypertrophy differs depending on the method of indexing left ventricular mass for body size and with the presence or absence of obesity. Further, the Cornell product provides the best combination of overall accuracy and low variability of performance between definitions of hypertrophy. These findings have important implications for the clinical and epidemiologic use of 12-lead ECG criteria for the detection of left ventricular hypertrophy.

This article has been cited by other articles:

				E. W. Hancock, B. J. Deal, D. M. Mirvis, P. Okin, P. Kligfield, and L. S. Gettes AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram: Part V: Electrocardiogram Changes Associated With Cardiac Chamber Hypertrophy A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society Endorsed by the International Society for Computerized Electrocardiology J. Am. Coll. Cardiol., March 17, 2009; 53(11): 992 - 1002. [Full Text] [PDF]

				E. W. Hancock, B. J. Deal, D. M. Mirvis, P. Okin, P. Kligfield, and L. S. Gettes AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram: Part V: Electrocardiogram Changes Associated With Cardiac Chamber Hypertrophy: A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: Endorsed by the International Society for Computerized Electrocardiology Circulation, March 17, 2009; 119(10): e251 - e261. [Full Text] [PDF]

				P. M. Okin, R. B. Devereux, K. E. Harris, S. Jern, S. E. Kjeldsen, L. H. Lindholm, B. Dahlof, and for the LIFE Study Investigators In-Treatment Resolution or Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Decreased Incidence of New-Onset Diabetes Mellitus in Hypertensive Patients: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study Hypertension, November 1, 2007; 50(5): 984 - 990. [Abstract] [Full Text] [PDF]

				T. A. Aksnes, S. E. Kjeldsen, M. Rostrup, P. Omvik, T. A. Hua, and S. Julius Impact of New-Onset Diabetes Mellitus on Cardiac Outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial Population Hypertension, September 1, 2007; 50(3): 467 - 473. [Abstract] [Full Text] [PDF]

				H. Mitsuhashi, H. Yatsuya, K. Tamakoshi, K. Matsushita, R. Otsuka, K. Wada, K. Sugiura, S. Takefuji, Y. Hotta, T. Kondo, et al. Adiponectin Level and Left Ventricular Hypertrophy in Japanese Men Hypertension, June 1, 2007; 49(6): 1448 - 1454. [Abstract] [Full Text] [PDF]

				N. Nobakhthaghighi, M. Kamgar, M. R. Bekheirnia, K. McFann, R. Estacio, and R. W. Schrier Relationship between Urinary Albumin Excretion and Left Ventricular Mass with Mortality in Patients with Type 2 Diabetes Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1187 - 1190. [Abstract] [Full Text] [PDF]

				S. S. Franklin, K. Wachtell, V. Papademetriou, M. H. Olsen, R. B. Devereux, F. Fyhrquist, H. Ibsen, S. E. Kjeldsen, and B. Dahlof Cardiovascular Morbidity and Mortality in Hypertensive Patients With Lower Versus Higher Risk: A LIFE Substudy Hypertension, September 1, 2005; 46(3): 492 - 499. [Abstract] [Full Text] [PDF]

				R. B. Devereux, B. Dahlof, S. E. Kjeldsen, S. Julius, P. Aurup, G. Beevers, J. M. Edelman, U. de Faire, F. Fyhrquist, Sigrid Helle Berg, et al. Effects of Losartan or Atenolol in Hypertensive Patients without Clinically Evident Vascular Disease: A Substudy of the LIFE Randomized Trial Ann Intern Med, August 5, 2003; 139(3): 169 - 177. [Abstract] [Full Text] [PDF]

				S. E. Kjeldsen, B. Dahlof, R. B. Devereux, S. Julius, P. Aurup, J. Edelman, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, et al. Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy: A Losartan Intervention For Endpoint Reduction (LIFE) Substudy JAMA, September 25, 2002; 288(12): 1491 - 1498. [Abstract] [Full Text] [PDF]

				P. M. Okin, R. B. Devereux, S. Jern, S. E. Kjeldsen, S. Julius, and B. Dahlof Baseline Characteristics in Relation to Electrocardiographic Left Ventricular Hypertrophy in Hypertensive Patients : The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study Hypertension, November 1, 2000; 36(5): 766 - 773. [Abstract] [Full Text] [PDF]

				C. Jaggy, F. Perret, P. Bovet, G. van Melle, N. Zerkiebel, G. Madeleine, L. Kappenberger, and F. Paccaud Performance of Classic Electrocardiographic Criteria for Left Ventricular Hypertrophy in an African Population Hypertension, July 1, 2000; 36(1): 54 - 61. [Abstract] [Full Text] [PDF]

				K. Wachtell, J. N. Bella, P. R. Liebson, E. Gerdts, B. Dahlof, T. Aalto, M. J. Roman, V. Papademetriou, H. Ibsen, J. Rokkedal, et al. Impact of Different Partition Values on Prevalences of Left Ventricular Hypertrophy and Concentric Geometry in a Large Hypertensive Population : The LIFE Study Hypertension, January 1, 2000; 35(1): 6 - 12. [Abstract] [Full Text] [PDF]

				P. M. Okin, S. Jern, R. B. Devereux, S. E. Kjeldsen, B. Dahlof, and f. t. L. S. Group Effect of Obesity on Electrocardiographic Left Ventricular Hypertrophy in Hypertensive Patients : The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study Hypertension, January 1, 2000; 35(1): 13 - 18. [Abstract] [Full Text] [PDF]

				C. N. Bairey Merz, S. F. Kelsey, C. J. Pepine, N. Reichek, S. E. Reis, W. J. Rogers, B. L. Sharaf, G. Sopko, and for the WISE Study Group The Women's Ischemia Syndrome Evaluation (WISE) Study: protocol design, methodology and feasibility report J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1453 - 1461. [Abstract] [Full Text] [PDF]

				P. M. Okin, M. J. Roman, R. B. Devereux, T. G. Pickering, J. S. Borer, and P. Kligfield Time-Voltage QRS Area of the 12-Lead Electrocardiogram : Detection of Left Ventricular Hypertrophy Hypertension, April 1, 1998; 31(4): 937 - 942. [Abstract] [Full Text] [PDF]